Why Viking Therapeutics Stock Is Up More Than 9% Today

Novo Nordisk's weight-loss drug CagriSema failed to meet a critical goal in late-stage clinical trials. This shortcoming bodes well for pharmaceutical companies working on similar obesity treatments.

The Motley Fool • Feb 23, 2026

3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds

Viking Therapeutics aims to enter the billion-dollar weight loss drug market. The company is studying a candidate in a phase 3 trial.

The Motley Fool • Feb 23, 2026

Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.

Viking Therapeutics' leading candidate posted strong mid-stage data and is undergoing phase 3 studies. Though there are some risks, the stock could soar if it can pass the upcoming clinical and regulatory hurdles.

The Motley Fool • Feb 24, 2026

Viking Therapeutics Stock Gains Amid Obesity Drug Buzz

Novo Nordisk's stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly's tirzepatide, marketed under the Zepbound and Mounjaro brands.

Benzinga • Feb 23, 2026

Is Viking Therapeutics Stock Really Going to $125?

Viking Therapeutics is nearly done developing and testing a potential GLP-1 weight loss drug. While the company is still losing money, the underlying business appears solid.

The Motley Fool • Feb 19, 2026

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street

Biotech companies could add growth to your portfolio -- and in some cases, at a bargain price. It's a great idea to select tomorrow's potential winners and hold on as their stories unfold.

The Motley Fool • Feb 19, 2026

2026 Could Be a Big Year for Viking Therapeutics. Time to Buy?

Viking Therapeutics is working to join a market that may be worth almost $100 billion in just a few years. The company is studying a candidate for weight loss in late-stage trials.

The Motley Fool • Feb 17, 2026

Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.

24/7 Wall Street • Feb 16, 2026

Viking Therapeutics: Full-Speed Ahead

Viking Therapeutics is aggressively advancing its GLP-1 pipeline, with two pivotal Phase 3 trials now underway or imminent. VKTX's Phase 2 oral data showed up to 14.7% weight loss in 13 weeks, positioning it competitively against current market leaders. With a $3.5B market cap and $706M cash, VKTX trades at a compelling discount to recent sector M&A benchmarks.

Seeking Alpha • Feb 14, 2026

Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential

Viking Therapeutics is still kept as a speculative buy, with selling pressure subsiding and constructive consolidation signaling renewed investor interest. VKTX's dual-track pipeline and manufacturing agreements position it to rapidly scale commercialization upon regulatory approval, despite a volatile and competitive GLP-1 market. Management's flexible go-to-market strategy and recent commercial leadership appointment highlight readiness to compete independently or via partnership.

Seeking Alpha • Feb 13, 2026